|
| 37495480 | Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide. | Clin Genitourin Cancer | 2024 |
| 37495480 | Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide. | Clin Genitourin Cancer | 2024 |
| 36104504 | Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. | Prostate Cancer Prostatic Dis | 2023 |
| 36104504 | Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. | Prostate Cancer Prostatic Dis | 2023 |
| 37594915 | United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism. | Expert Opin Drug Saf | 2023 |
| 36811981 | Humira: the first $20 billion drug. | Am J Manag Care | 2023 |
| 36872463 | Accelerated approval drug labels often lack information for clinical decision-making. | Pharmacotherapy | 2023 |
| 37253974 | Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. | Prostate Cancer Prostatic Dis | 2023 |
| 37037322 | Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020). | J Clin Epidemiol | 2023 |
| 37594915 | United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism. | Expert Opin Drug Saf | 2023 |
| 37253974 | Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. | Prostate Cancer Prostatic Dis | 2023 |
| 37037322 | Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020). | J Clin Epidemiol | 2023 |
| 36811981 | Humira: the first $20 billion drug. | Am J Manag Care | 2023 |
| 36872463 | Accelerated approval drug labels often lack information for clinical decision-making. | Pharmacotherapy | 2023 |
| 34971576 | Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. | Lancet Haematol | 2022 |
| 36371107 | EDITORIAL COMMENT. | Urology | 2022 |
| 36153104 | EDITORIAL COMMENT. | Urology | 2022 |
| 35605235 | Medicare Spending on Drugs With Accelerated Approval. | Ann Intern Med | 2022 |
| 36449195 | Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth. | Cancer Treat Res | 2022 |
| 36449194 | Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR). | Cancer Treat Res | 2022 |
| 36449193 | Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work. | Cancer Treat Res | 2022 |
| 36449192 | Maximum Accuracy Machine Learning Statistical Analysis-A Novel Approach. | Cancer Treat Res | 2022 |
| 36449191 | Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update. | Cancer Treat Res | 2022 |
| 36449189 | Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions. | Cancer Treat Res | 2022 |
| 36449190 | Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen. | Cancer Treat Res | 2022 |
| 36449188 | Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration. | Cancer Treat Res | 2022 |
| 36449187 | Policing of Drug Safety Information Dissemination Under the False Claims Act. | Cancer Treat Res | 2022 |
| 36449186 | Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions. | Cancer Treat Res | 2022 |
| 36449185 | Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years. | Cancer Treat Res | 2022 |
| 34971576 | Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. | Lancet Haematol | 2022 |
| 35093531 | Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. | J Clin Epidemiol | 2022 |
| 35605235 | Medicare Spending on Drugs With Accelerated Approval. | Ann Intern Med | 2022 |
| 36449195 | Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth. | Cancer Treat Res | 2022 |
| 36449194 | Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR). | Cancer Treat Res | 2022 |
| 36449193 | Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work. | Cancer Treat Res | 2022 |
| 36449192 | Maximum Accuracy Machine Learning Statistical Analysis-A Novel Approach. | Cancer Treat Res | 2022 |
| 36449191 | Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update. | Cancer Treat Res | 2022 |
| 36449189 | Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions. | Cancer Treat Res | 2022 |
| 36449190 | Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen. | Cancer Treat Res | 2022 |
| 36449188 | Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration. | Cancer Treat Res | 2022 |
| 36449187 | Policing of Drug Safety Information Dissemination Under the False Claims Act. | Cancer Treat Res | 2022 |
| 36449186 | Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions. | Cancer Treat Res | 2022 |
| 36449185 | Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years. | Cancer Treat Res | 2022 |
| 36371107 | EDITORIAL COMMENT. | Urology | 2022 |
| 36153104 | EDITORIAL COMMENT. | Urology | 2022 |
| 35093531 | Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. | J Clin Epidemiol | 2022 |
| 33337916 | Contemporary Clinical Trials Office: Doing More With Less. | JCO Oncol Pract | 2021 |
| 33586299 | The First 2â¿¿Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. | Oncologist | 2021 |
| 33526699 | Cytoplasmic synthesis of endogenous <i>Alu</i> complementary DNA via reverse transcription and implications in age-related macular degeneration. | Proc Natl Acad Sci U S A | 2021 |
| 33836289 | A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999-2015. | Ann Epidemiol | 2021 |